Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company’s ...

Sionna said these molecules, two correctors and one potentiator, could be combined with its NBD1 stabilizers. Prior to the ...

Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and SION-451 to a Phase 1 healthy volunteer dual combination trial .

Sionna’s shares are scheduled to begin trading on the Nasdaq Global Market on February 7, 2025 under the ticker symbol "SION.

Sionna Therapeutics reports Phase 1 trial progress for CF treatments, an IPO success, and plans for upcoming trials. Quiver AI Summary. Sionna Therapeutics, Inc. has successfully completed the ...

Sionna has ongoing Phase 1 trials of its two NBD1 stabilizers, SION-719 and SION-451. As of Dec. 31, 2024 the company had 35 full-time employees.

Sionna Therapeutics, Inc. has announced the presentation of promising preclinical data at the 48th European Cystic Fibrosis Conference in Milan, showing that its nucleotide-binding domain 1 (NBD1 ...

BOSTON, Aug. 13, 2024 /PRNewswire/ -- Sionna Therapeutics, a clinical-stage life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF ...

Sionna has its own TMD1-directed corrector, SION-676, in preclinical development, plus an ICL4-targeted candidate, SION-109, in phase 1. The expansion of the pipeline gives Sionna a choice to make.

Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and SION-451 to a Phase 1 healthy volunteer dual combination trial .

Sionna said these molecules, two correctors and one potentiator, could be combined with its NBD1 stabilizers. Prior to the IPO, Sionna said it had raised about $330 million from investors.